You're expecting Leronlimab will not benefit stage

You're expecting Leronlimab will not benefit stage 3/4 cancer patients.

Okay. But what if it does?
We'll find out shortly.
And if it benefits stage 3/4 patients, given the safety profile and low toxation, would that not make it probable doctors prescribing it for stage 1/2 patients (can't hurt, can't kill?).
Even phase 1/2 cancer patients might benefit far sooner then when Cydy started up multiple years trials especially for the phase 1/2 group.

You're expecting Leronlimab not working for stage 3/4 cancer patients but it might be beneficial for stage 1/2.
If there is truth in that and Cydy thinks that too then they could always start those trials up later (when revenue is coming in from HIV-sales).

If it works for stage 3/4. Great! If it doesn't work but can for phase 1/2. Start up phase 1/2 when funds available.
I don't see how they are shooting themselves in the foot.

On the contrary they're doing exactly the right thing.

Also, I feel that anything that has potential to work be it only for certain cancers for only some people with specific receptors needs to be researched. If it can prevent metastasis for that specific group that's great on itself.